Holen Sie sich die Stockscreener-App
16.57
0.48%
-0.08
Handel nachbörslich:
16.52
-0.05
-0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$16.65
Offen:
$16.57
24-Stunden-Volumen:
686.26K
Relative Volume:
0.48
Marktkapitalisierung:
$2.20B
Einnahmen:
$298.30M
Nettoeinkommen (Verlust:
$298.21M
KGV:
7.6582
EPS:
2.1637
Netto-Cashflow:
$166.93M
1W Leistung:
+8.37%
1M Leistung:
+7.95%
6M Leistung:
+13.57%
1J Leistung:
+35.04%
1-Tages-Spanne:
$16.31
$16.68
1-Wochen-Bereich:
$15.15
$17.80
52-Wochen-Spanne:
$10.34
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.57 | 2.30B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Hochstufung | Jefferies | Hold → Buy |
| 2025-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - TradingView
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Aurinia Settles Patent Litigation with Teva - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aurinia (AUPH) Latest Price Review: Rises 0.07% to $15.30 in the Current Update; Level Check: the Near-Term Reference Band Stretches From $14.54 to $16.07 under the Current SnapshotETF Outflow Streak - Vinanet
Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% UpQuarterly Profit Report - vinanet.vn
(AUPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Aurinia Pharmaceuticals advances Lupkynis in ph... - Pluang
Aurinia Pharmaceuticals Doubles Down On Its Pipeline (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Navigating Growth in Biotech with a 10% Upside Potential - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance - simplywall.st
Aurinia Pharmaceuticals Announces Q2 2026 Financial Results with Strong Revenue and Income Growth - Kalkine Media
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28— 10-Q Summary - TradingView
AUPH: Strong revenue and profit growth fueled by LUPKYNIS sales and disciplined capital allocation - TradingView
Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance - TradingView
Aurinia Q2 revenue rises 19 percent to $83.2 million - Quiver Quantitative
AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook - TradingView
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M - Moomoo
BRIEF-Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million - TradingView
(AUPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Uncovering a 16.68% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain - simplywall.st
Lazard Asset Management LLC Sells 106,820 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc Revenue Breakdown – NASDAQ:AUPH - TradingView
Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharma earnings up next as growth momentum faces test By Investing.com - Investing.com UK
OMERS ADMINISTRATION Corp Takes Position in Aurinia Pharmaceuticals Inc $AUPH - marketbeat.com
AUPH Q2'26 Earnings: EPS estimate is 0.24 USD - TradingView
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):